Promising Phase III data for a new passive vaccine against RSV
May 10, 2021Infection by Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in infants. The currently available preventive treatment is a monthly injection with an anti-RSV antibody, which is only given to high-risk infants and only temporarily provides protection due to a limited half-life. Now, a new antibody against RSV, which was developed by scientists of Amsterdam UMC
spin-off AIMM Therapeutics, has come one step closer to market authorization, showing positive results in a Phase III clinical trial performed by pharma companies Astra Zeneca and Sanofi. This antibody, being more stable than the existing antibody, will only need to be administered once per RSV-season and should become available to all infants.
For more information click here.
Photo credit: Respiratory syncytial virus (RSV) infection – Case 288 by Yale Rosen. Photo is cropped.
More news
Tackling learning difficulties in Academic Workplace
The Academic Workplace Rudolf Berlin Center (AW RBC) aims to make a meaningful contribution by supporting young people with learning disabilities through enhanced education and care.
News
VU researchers develop research equipment to identify contaminants in water
Water, comprising over 70% of our planet, is the source of all life. The presence of emerging contaminants in our water, including pharmaceuticals, pose serious health and environmental risks, such as DNA damage, reproductive issues, and cancer. New equipment to detect these contaminants developed by VU researchers has been sold to other research groups all over the world. Now the researchers are taking the next step, together with IXA, to expand sales to water companies worldwide as well as other applications such as food and drug discovery research.
News
Contribute to Amsterdam’s Future: test your innovation at SAIL and the Amsterdam Marathon
Are you looking for a testing ground for your innovation? SAIL and the Amsterdam Marathon present an excellent opportunity to test your ideas. These major events attract millions of visitors and come with sustainability, accessibility, and logistical challenges that need fresh solutions. The In Residence Events program allows you to test your innovation during these […]
News